Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Johnson and Johnson
Cantor Fitzgerald
Express Scripts
Fuji
Merck
McKesson
Fish and Richardson
Julphar
Citi

Generated: January 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,858,650

« Back to Dashboard

Which drugs does patent 6,858,650 protect, and when does it expire?

Patent 6,858,650 protects TOVIAZ and is included in one NDA.

This patent has sixty-nine patent family members in twenty-nine countries.
Summary for Patent: 6,858,650
Title: Stable salts of novel derivatives of 3,3-diphenylpropylamines
Abstract:The present invention concerns highly pure, crystalline, stable compounds of novel derivatives of 3,3-diphenylpropylamines in the form of their salts, a method for the manufacture and highly pure, stable intermediate products. The method is in particular characterized by regio- and chemoselectivity and high yield. Salts of phenolic monoesters of 3,3-diphenylpropylamines are provided, that are particularly well-suited for use in pharmaceutical formulations. Preferred compounds are R-(+)-2-(3-diisopropylamino-1-phenyl-propyl)-4-hydroxymethylphenylisobutyr ate ester hydrogen fumarate and R-(+)-2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenylisobutyra te ester hydrochloride hydrate. Furthermore, stable, crystalline intermediate products that are essential for obtaining the abovementioned salts are provided. A preferred intermediate product is R-(-)-3-(3-diisopropylamino-phenyl-propyl)-4-hydroxy-benzoic acid methyl ester.
Inventor(s): Meese; Claus (Monheim, DE)
Assignee: Schwarz Pharma AG (DE)
Application Number:10/130,214
Patent Claim Types:
see list of patent claims
Compound; Formulation; Use;

Drugs Protected by US Patent 6,858,650

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Pfizer TOVIAZ fesoterodine fumarate TABLET, EXTENDED RELEASE;ORAL 022030-001 Oct 31, 2008 AB RX Yes No ➤ Subscribe ➤ Subscribe Y TREATMENT OF OVERACTIVE BLADDER WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND FREQUENCY ➤ Subscribe
Pfizer TOVIAZ fesoterodine fumarate TABLET, EXTENDED RELEASE;ORAL 022030-002 Oct 31, 2008 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y TREATMENT OF OVERACTIVE BLADDER WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND FREQUENCY ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,858,650

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany199 55 190Nov 16, 1999
PCT Information
PCT FiledNovember 15, 2000PCT Application Number:PCT/EP00/11309
PCT Publication Date:May 25, 2001PCT Publication Number: WO01/35957

International Patents Family Members for US Patent 6,858,650

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Slovenia 1230209 ➤ Subscribe
Portugal 1690536 ➤ Subscribe
Portugal 1481964 ➤ Subscribe
Portugal 1230209 ➤ Subscribe
Poland 201422 ➤ Subscribe
Poland 356766 ➤ Subscribe
New Zealand 519230 ➤ Subscribe
Norway 332637 ➤ Subscribe
Norway 20065380 ➤ Subscribe
Norway 323920 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Express Scripts
Healthtrust
US Army
Farmers Insurance
Mallinckrodt
Daiichi Sankyo
Deloitte
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot